An evaluation of afamitresgene autoleucel for the treatment of advanced synovial sarcoma and myxoid round cell liposarcoma
Afami-cel represents a milestone in sarcoma therapy, establishing proof of concept for engineered TCR T-cell therapies in solid tumors. However, challenges remain regarding HLA restriction, tumor microenvironment resistance, manufacturing delays and cost. Future efforts should focus on broadening applicability, optimizing combinations, and ensuring equitable access.
Authors
- Jean‐Yves Blay (ORCID: https://orcid.org/0000-0001-7190-120X)
- Margaux Dupont (ORCID: https://orcid.org/0009-0002-0959-1460)
- Clémence Romeo (ORCID: https://orcid.org/0000-0003-1280-8069)
- Armelle Dufresne
- Mehdi Brahmi
Institutions
- Centre Léon Bérard (FR)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1080/14737140.2025.2612043
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00